SPY305.55+1.23 0.40%
DIA255.27+0.98 0.39%
IXIC9,552.05+62.18 0.66%

Turning Point Therapeutics Commences $250M Stock Offering, Company Says it Expects Preliminary Data From Phase 2 Studies of Trident-1 in 2H 2020

Benzinga · 05/18/2020 11:12